Clinical Trial Update: Study of AMDX-2011P as a Retinal Tracer in Subjects With Neurodegenerative Diseases Associated With Amyloidogenic Proteinopathy [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 study of AMDX-2011P as a retinal tracer in Parkinson's disease and Amyotrophic Lateral Sclerosis has completed enrollment. Results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Amyotrophic Lateral Sclerosis
• Parkinson Disease

Drugs mentioned

• AMDX-2011P

Snippet

Sponsor: Amydis Inc. | Conditions: Parkinson Disease, Amyotrophic Lateral Sclerosis | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2025-08-20